Dimethyl fumarate and extracorporeal photopheresis combination-therapy synergize in inducing specific cell death and long-term remission in cutaneous T cell lymphoma

Sener, Oezge C. and Melchers, Susanne and Tengler, Luisa and Beltzig, Paul L. and Albrecht, Jana D. and Tuemen, Deniz and Guelow, Karsten and Utikal, Jochen S. and Goerdt, Sergij and Hein, Tobias and Nicolay, Jan P. (2025) Dimethyl fumarate and extracorporeal photopheresis combination-therapy synergize in inducing specific cell death and long-term remission in cutaneous T cell lymphoma. LEUKEMIA, 39 (2). pp. 438-450. ISSN 0887-6924, 1476-5551

Full text not available from this repository. (Request a copy)

Abstract

Primary cutaneous T cell lymphomas (CTCL) are characterized by high relapse rates to initially highly effective therapies. Combination therapies have proven beneficial, particularly if they incorporate extracorporeal photopheresis (ECP). The NF-kappa B inhibitor dimethyl fumarate (DMF) has proven a new, effective drug in CTCL in a clinical phase II study. In vitro experiments with patient-derived SS cells and the CTCL cell lines HH, HuT 78, and SeAx revealed a synergistic effect of DMF and ECP on cell death induction in CTCL cells. Furthermore, an additional increase in the capacity to inhibit NF-kappa B in CTCL was detected for the combination treatment compared to DMF monotherapy. The same synergistic effects could be measured for ROS production via decreased Thioredoxin reductase activity and glutathione levels. Consequently, a cell death inhibitor screen indicated that the DMF/ECP combination treatment induces a variety of cell death mechanisms in CTCL. As a first step into clinical translation, 4 patients were already treated with the DMF/ECP combination therapy with an overall response rate of 100% and a time to next treatment in skin and blood of up to 57 months. Therefore, our study introduces the combination treatment of DMF and ECP as a highly effective and long-lasting CTCL therapy.

Item Type: Article
Uncontrolled Keywords: NF-KAPPA-B; SEZARY-SYNDROME; NUCLEAR-FACTOR; ACTIVATION; RESISTANCE; APOPTOSIS; PHOTOCHEMOTHERAPY; CYTOTOXICITY; EXPRESSION; CYTOKINES;
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin I
Depositing User: Dr. Gernot Deinzer
Date Deposited: 31 Mar 2026 06:51
Last Modified: 31 Mar 2026 06:51
URI: https://pred.uni-regensburg.de/id/eprint/65132

Actions (login required)

View Item View Item